Kissei Over Active Bladder Agent Phase III Fails To Meet Endpoint
This article was originally published in PharmAsia News
Executive Summary
Kissei Pharmaceutical announced that preliminary analysis of a Phase III study of KUC-7483 for overactive bladder indicated that the drug did not meet its primary efficacy endpoint